PTPRC and neoplasm: Tumor infiltrating immune cell analysis by immunohistochemistry showed no changes in the number of CD163+ M2-like macrophages (Supplementary Fig. 1B), CD4+ (Supplementary Fig. 1C) or B220+ (Supplementary Fig. 1D) cells in the different therapy groups.